TG Therapeutics (TGTX) Gets Boost from Trial Data; Concert Pharma (CNCE) Inks Mega-Deal with Vertex Pharma (VRTX)


Shares of TG Therapeutics Inc. (Nasdaq:TGTX) soared more than 50% in pre-market trad Monday after the company said that data from a late-stage study showed that its glycoengineered monoclonal antibody TG-1101 (ublituximab) combined with ibrutinib performed significantly better in Overall Response Rate versus ibrutinib alone – the study’s primary endpoint – in patients with high risk Chronic Lymphocytic Leukemia, a type of cancer that starts from white blood cells (lymphocytes) in the bone marrow.

TGTX stock closed at $5.35, down $0.25 (or -4.46%) on Friday.

TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases, has 54.73M shares outstanding and TGTX stock 52-week range is from $4.10 to $10.50 per share. At close on Friday, the biopharmaceutical company had a market capitalization of $292.81M



Concert Pharmaceuticals, Inc. (Nasdaq:CNCE) shares climbed over 25% before the opening bell Monday as the company said that Vertex Pharmaceuticals, Inc. (Nasdaq:VRTX) will acquire all rights to its investigational cystic fibrosis treatment CTP-656.

The deal calls, among other things, for Vertex to pay Concert $160 million in cash – upon closing – and up to $90 million based on the achievement of pre-determined product milestones.

CNCE stock finished Friday’s trading session in opositive territory by 0.52% (or +$0.05) at $9.65

Concert Pharmaceuticals, which discovers and develops small molecule drugs for genetic diseases, inflammatory disease, and neurologic disorders, has 22.27M shares outstanding, market capitalization (intraday) of $214.95M and ECNCE stock one-year range is between $7.11 and $15.53 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at